Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Medtronic's (MDT) Medicrea Buyout to Aid AI Spinal Surgery Line
by Zacks Equity Research
Medtronic (MDT) expects Medicrea's capabilities and solutions to complement its fully-integrated procedural solution for surgical planning and delivery.
QIAGEN (QGEN) Launches PCR Test, Expands Testing Portfolio
by Zacks Equity Research
QIAGEN (QGEN) aims to expand its NeuMoDx testing menu with the latest test launch and label extension.
Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows
by Zacks Equity Research
Teleflex (TFX) expects further adverse financial impact of the coronavirus pandemic.
AngioDynamics (ANGO) Shows Solid Results from RAPID Database
by Zacks Equity Research
The RAPID study proved that AngioDynamics' (ANGO) AngioVac System was versatile, safe and effective for the removal of vascular thrombi and cardiac masses.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) on robust growth of the Diagnostics segment and regulatory approvals.
Hologic (HOLX) Updates Its Unifi Platform, Enhances Portfolio
by Zacks Equity Research
Hologic (HOLX) introduces upgrades to its Unifi Analytics platform to help mammography centers improve their workflow.
Ecolab Introduces Exelerate TUFSOIL for Food Manufacturers
by Zacks Equity Research
Ecolab's (ECL) Exelerate TUFSOIL has been developed to increase production time and enhance cleaning outcomes to curb food safety risks and improve worker safety.
Abbott (ABT) Launches Radiofrequency Ablation Device in U.S.
by Zacks Equity Research
Abbott (ABT) aims to expand its Neuromodulation portfolio with the latest launch of its radiofrequency ablation device.
Becton Dickinson (BDX) Buys Medical Business Assets of CUBEX
by Zacks Equity Research
This should further boost BD's (BDX) Medical segment.
Tivity Health's (TVTY) Shares Fall Despite Q3 Earnings Beat
by Zacks Equity Research
Tivity Health (TVTY) reports solid revenue growth in its Nutrition arm in the third quarter due to strength in Nutrisystem brand DTC.
HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings
by Zacks Equity Research
HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.
Owens & Minor's (OMI) Shares Fall Despite Q3 Earnings Beat
by Zacks Equity Research
Owens & Minor (OMI) reports solid revenue growth in its Global Products arm in the third quarter due to strength in PPE sales.
AMN Healthcare (AMN) Loses 9.4% Despite Q3 Earnings Beat
by Zacks Equity Research
AMN Healthcare (AMN) gained from Technology and Workforce Solutions segment in the third quarter.
Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)
by Zacks Equity Research
Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.
Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y
by Zacks Equity Research
In Q3, Hill-Rom's (HRC) bed orders and backlog in the United States accelerates with sequential recovery in Patient Support Systems arm.
Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3
by Zacks Equity Research
Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.
Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.
Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates
by Zacks Equity Research
Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.
Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.
Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3
by Zacks Equity Research
Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
CVS Health (CVS) Q3 Earnings Top Estimates, 2020 View Up
by Zacks Equity Research
CVS Health's (CVS) Q3 pharmacy claims processed rise attributable to strong net new business, partially offset by reduced new therapy prescriptions.
Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.